Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nebularine is a naturally occurring purine nucleoside analog, structurally similar to adenosine but lacking an amino group at the C6 position. It acts as a potent inhibitor of adenosine deaminase, thereby interfering with the metabolism of adenosines and affecting DNA, RNA, and protein synthesis. Nebularine exhibits cytotoxic properties and has demonstrated anticancer activity in preclinical studies, particularly against certain lymphoid malignancies. Additionally, it shows anti-mycobacterial (including tuberculostatic), antifungal, and antiviral (notably anti-herpes) activities. Its mechanism involves inhibition of DNA/RNA synthesis as well as direct enzyme inhibition[1][3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nebularine.